trending Market Intelligence /marketintelligence/en/news-insights/trending/MJzKNxwhbEDYtuA-JuhXWQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Akeso Biopharma files for Hong Kong IPO

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Akeso Biopharma files for Hong Kong IPO

Akeso Biopharma Inc. filed to list its shares on the Hong Kong Stock Exchange.

The Guangdong, China-based privately held life sciences tools and services company acts as a contract research organization for pharmaceutical companies that focus on developing antibody drugs and protein-based drugs.

Akeso Biopharma previously announced that it received about $150 million in funding from existing and new investors.

Moreover, it entered into a joint venture in June with privately held pharmaceutical Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd. to develop and commercialize a PD-1 antibody called AK105.